283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

• Alexander Stevenson,
• Jianjun Gao,
• Pavlos Msaouel,
• Nizar Tannir,
• Mehmet Altan,
• Shi-Ming Tu,
• Michael Chisamore,
• Matthew Campbell,
• George Blumenschein,
• Xiuning Le,
• Frank Mott,
• Amishi Shah,
• Jordi Rodon,
• Imke Mulder

Affiliations

Alexander Stevenson

24D pharma plc, Leeds, UK

Jianjun Gao

1 Department of Nephrology, Chinese PLA Strategic Support Force Characteristic Medical Center (The 306th Hospital of Chinese PLA), Beijing, China

Pavlos Msaouel

1MD Anderson Cancer Center, Houston, TX, USA

Nizar Tannir

Aff9 0000 0001 2291 4776grid.240145.6Department of Genitourinary Medical OncologyThe University of Texas MD Anderson Cancer Center Houston TX USA

Mehmet Altan

Aff9 0000 0001 2291 4776grid.240145.6Thoracic Head and Neck Medical OncologyThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX USA

Shi-Ming Tu

Aff2 grid.240145.60000000122914776Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center Unit 1374, 1155 Pressler Street 77030-3721 Houston TX USA

Michael Chisamore

2Merch and Co., Inc., Rahway, NJ, USA

Matthew Campbell

Institute of Genetics, University of Dublin, Trinity College, Dublin, Ireland

George Blumenschein

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Xiuning Le

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Frank Mott

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Amishi Shah

1MD Anderson Cancer Center, Houston, TX, USA

Jordi Rodon

1MD Anderson Cancer Center, Houston, TX, USA

Imke Mulder

24D pharma plc, Leeds, UK